Endometrial Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: END041 MIFTS: 60	Endometrial Adenocarcinoma Categories: Cancer diseases, Reproductive diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Endometrial Adenocarcinoma

MalaCards integrated aliases for Endometrial Adenocarcinoma:

Name: Endometrial Adenocarcinoma ¹¹ ¹⁴ ⁷¹

Endometrial Endometrioid Adenocarcinoma ¹¹ ¹⁶ ⁷¹ ³³

Endometrial Endometrioid Adenocarcinoma, Variant with Squamous Differentiation ⁵ ¹⁶

Endometrial Adenoacanthoma ¹¹ ⁷¹

Endometrial Endometrioid Adenocarcinoma with Squamous Differentiation ¹¹

Endometrioid Carcinoma of Endometrium ¹¹

Endometrioid Adenomas and Carcinomas ¹¹

Adenocarcinoma of the Endometrium ¹¹

Endometrioid Adenoma or Carcinoma ¹¹

Adenocarcinoma of Endometrium ¹¹

Endometrium Adenocarcinoma ¹⁶

Adenocarcinoma of Uterus ¹¹

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

ICD11: ³³

Neoplasms

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms of female genital organs

Malignant neoplasms of corpus uteri

Endometrial endometrioid adenocarcinoma

External Ids:

Disease Ontology ¹¹ DOID:2870

NCIt ⁴⁹ C6287 C6290 C7359

SNOMED-CT ⁶⁸ 123845008 762458004

EFO ¹⁶ EFO_0005232 EFO_1000233 EFO_1001953

ICD11 ³³ 671511103

UMLS ⁷¹ C0279763 C1153706 C1336905

Sources

Summaries for Endometrial Adenocarcinoma

Disease Ontology: ¹¹ An endometrial carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary: Endometrial Adenocarcinoma, also known as endometrial endometrioid adenocarcinoma, is related to adenocarcinoma and endometrial hyperplasia. An important gene associated with Endometrial Adenocarcinoma is MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), and among its related pathways/superpathways are Signal Transduction and Phospholipase-C Pathway. The drugs Bupivacaine and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include uterus, lymph node and ovary, and related phenotypes are neoplasm and muscle

Sources

Related Diseases for Endometrial Adenocarcinoma

Diseases related to Endometrial Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 545)

#	Related Disease	Score	Top Affiliating Genes
1	adenocarcinoma	32.0	TP53 PTEN MALAT1 FGFR2 EGFR AKT1
2	endometrial hyperplasia	31.3	TP53 PTEN PGR ESR1
3	endometrial cancer	31.2	TP53 PTEN PIK3R2 PGR MIR200B MIR200A
4	adenomyosis	31.1	TP53 PTEN ESR1
5	cervical adenocarcinoma	30.9	TP53 PGR ESR1
6	carcinosarcoma	30.8	TP53 PTEN PGR EGFR
7	estrogen excess	30.7	PTEN PGR ESR1
8	large cell neuroendocrine carcinoma	30.7	TP53 MIR200B EGFR
9	endocervical adenocarcinoma	30.7	TP53 PTEN PGR ESR1
10	neuroendocrine carcinoma	30.7	PTEN PGR ESR1
11	papillary serous adenocarcinoma	30.6	TP53 PGR ESR1
12	squamous cell carcinoma	30.6	TP53 PTEN MALAT1 FGFR2 EGFR AKT1
13	serous cystadenocarcinoma	30.6	TP53 PTEN PGR MIR152 ESR1 AKT1
14	lynch syndrome	30.5	TP53 PTEN PGR ESR1 EGFR AKT1
15	teratoma	30.5	TP53 PTEN ESR1 AKT1
16	leiomyosarcoma	30.5	TP53 PGR ESR1
17	endometriosis	30.5	TP53 PTEN PGR MIR200B MIR200A ESR1
18	endometrial stromal sarcoma	30.5	TP53 PGR MALAT1 ESR1
19	bizarre leiomyoma	30.5	TP53 PGR ESR1
20	papilloma	30.4	TP53 PTEN EGFR AKT1
21	myoma	30.3	TP53 PGR ESR1 EGFR
22	renal cell carcinoma, papillary, 1	30.3	TP53 PTEN EGFR AKT1
23	lymphatic system disease	30.3	TP53 MIR204 MIR200B MIR193A
24	uterine corpus endometrial carcinoma	30.3	TP53 PTEN PGR FGFR2
25	bilateral breast cancer	30.3	TP53 PTEN PGR ESR1
26	diffuse peritoneal leiomyomatosis	30.3	PGR ESR1
27	colorectal adenocarcinoma	30.3	TP53 PTEN MIR193A EGFR AKT1
28	fibroma	30.3	PGR MALAT1 ESR1
29	uterine corpus cancer	30.2	TP53 PTEN PGR ESR1 EGFR AKT1
30	adenosarcoma	30.2	TP53 PGR ESR1
31	endometrial disease	30.2	PGR MIR200A ESR1
32	ovary adenocarcinoma	30.2	TP53 PTEN PGR MIR152 ESR1 EGFR
33	ovarian clear cell carcinoma	30.2	TP53 PTEN AKT1
34	endometriosis of ovary	30.2	PTEN PGR ESR1
35	uterine anomalies	30.1	MIR204 MIR200B MIR200A MIR193A MIR152 ESR1
36	cervix carcinoma	30.1	TP53 PTEN PGR MIR200A MIR193A ESR1
37	rectum cancer	30.1	TP53 MIR200A MIR193A EGFR
38	endosalpingiosis	30.1	TP53 ESR1
39	basal cell nevus syndrome	30.1	TP53 PTEN AKT1
40	transitional cell carcinoma	30.1	TP53 PTEN FGFR2 EGFR
41	gastric adenocarcinoma	30.1	TP53 PTEN FGFR2 AKT1
42	ovarian disease	30.0	TP53 PTEN PGR MIR204 MIR202 MIR200B
43	rhabdomyosarcoma	30.0	TP53 PTEN ESR1 EGFR AKT1
44	kidney cancer	30.0	TP53 MIR204 MIR200B MIR193A MALAT1 EGFR
45	basal cell carcinoma	29.9	TP53 PTEN MIR200B EGFR AKT1
46	intestinal benign neoplasm	29.9	TP53 PTEN MIR200A MIR193A EGFR AKT1
47	colonic benign neoplasm	29.9	TP53 PTEN MIR200A ESR1 EGFR AKT1
48	hemangioma	29.9	TP53 PTEN PGR ESR1 EGFR AKT1
49	head and neck cancer	29.8	TP53 PTEN MIR204 MIR200B MIR200A MIR193A
50	gastrointestinal stromal tumor	29.8	TP53 PTEN MIR204 FGFR2 ESR1 EGFR

Graphical network of the top 20 diseases related to Endometrial Adenocarcinoma:

Sources

Symptoms & Phenotypes for Endometrial Adenocarcinoma

MGI Mouse Phenotypes related to Endometrial Adenocarcinoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	9.86	AKT1 EGFR ESR1 FGFR2 PGR PIK3R2
2	muscle	MP:0005369	9.76	AKT1 EGFR ESR1 FGFR2 PGR PIK3R2
3	adipose tissue	MP:0005375	9.5	AKT1 EGFR ESR1 FGFR2 PTEN RHOXF1
4	reproductive system	MP:0005389	9.32	AKT1 EGFR ESR1 FGFR2 MIR200B NDC80

Sources

Drugs & Therapeutics for Endometrial Adenocarcinoma

Drugs for Endometrial Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Dexmedetomidine

Approved, Experimental, Vet_approved

Phase 4

86347-14-0, 113775-47-6

68602 5311068

Ketamine

Approved, Vet_approved

Phase 4

6740-88-1, 1867-66-9

3821

Anesthetics

Phase 4

Neurotransmitter Agents

Phase 4

Adrenergic alpha-Agonists

Phase 4

Adrenergic Agonists

Phase 4

Adrenergic Agents

Phase 4

Excitatory Amino Acid Antagonists

Phase 4

Anesthetics, Local

Phase 4

Anesthetics, Intravenous

Phase 4

Anesthetics, General

Phase 4

Anesthetics, Dissociative

Phase 4

Hypnotics and Sedatives

Phase 4

Analgesics, Non-Narcotic

Phase 4

Analgesics

Phase 4

Doxorubicin

Approved, Investigational

Phase 3

23214-92-8

31703

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Pembrolizumab

Approved

Phase 3

1374853-91-4

254741536

Metformin

Approved

Phase 2, Phase 3

1115-70-4, 657-24-9

4091

Liposomal doxorubicin

Phase 3

Adjuvants, Immunologic

Phase 3

Hypoglycemic Agents

Phase 2, Phase 3

Estrogens

Phase 3

Hormones

Phase 3

Hormone Antagonists

Phase 3

Estrogens, Conjugated (USP)

Phase 3

Medroxyprogesterone acetate

Approved, Investigational

Phase 2

520-85-4, 71-58-9

6279 10631

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Amifostine

Approved, Investigational

Phase 2

20537-88-6

2141

Trastuzumab

Approved, Investigational

Phase 2

180288-69-1

Thalidomide

Approved, Investigational, Withdrawn

Phase 2

50-35-1

5426

Nintedanib

Approved

Phase 2

656247-17-5

135423438 9809715

Everolimus

Approved

Phase 2

159351-69-6

70789204 6442177

Letrozole

Approved, Investigational

Phase 2

112809-51-5

3902

Ipilimumab

Approved

Phase 2

477202-00-9

Levoleucovorin

Approved, Experimental, Investigational

Phase 1, Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Gemcitabine

Approved

Phase 1, Phase 2

95058-81-4, 122111-03-9

60750

Niraparib

Approved, Investigational

Phase 1, Phase 2

1038915-60-4

24958200

Irinotecan

Approved, Investigational

Phase 1, Phase 2

97682-44-5, 100286-90-6

60838

Fluorouracil

Approved

Phase 1, Phase 2

51-21-8

3385

Fulvestrant

Approved, Investigational

Phase 2

129453-61-8

17756771 104741

Exemestane

Approved, Investigational

Phase 2

107868-30-4

60198

Sirolimus

Approved, Investigational

Phase 1, Phase 2

53123-88-9

5284616 6436030

Anastrozole

Approved, Investigational

Phase 1, Phase 2

120511-73-1

2187

Nivolumab

Approved

Phase 2

946414-94-4

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Olaparib

Approved

Phase 1, Phase 2

763113-22-0

23725625

Interventional clinical trials:

(show top 50) (show all 77)

#	Name	Status	NCT ID	Phase	Drugs
1	Effects of Local Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Inflammatory Cytokines Response After Total Abdominal Hysterectomy	Completed	NCT03164590	Phase 4	Ketamine;dexmedetomidine;bupivacaine
2	A Randomized Phase III Study of Tumor Volume Directed Pelvic Plus or Minus Para-Aortic Irradiation Followed by Cisplatin and Doxorubicin or Cisplatin, Doxorubicin and Paclitaxel for Advanced Endometrial Carcinoma	Completed	NCT00006011	Phase 3	Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
3	A Phase III Randomized Clinical Trial of Laparoscopic Pelvic and Para-Aortic Node Sampling With Vaginal Hysterectomy and BSO Versus Open Laparotomy With Pelvic and Para-Aortic Node Sampling and Abdominal Hysterectomy and BSO in Endometrial Adenocarcinoma and Uterine Sarcoma, Clinical Stage I, IIA, Grade I, II, III	Completed	NCT00002706	Phase 3
4	A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer	Active, not recruiting	NCT03914612	Phase 3	Carboplatin;Paclitaxel
5	A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer	Active, not recruiting	NCT04214067	Phase 3
6	Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE)	Active, not recruiting	NCT03422198	Phase 3
7	A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer	Active, not recruiting	NCT02065687	Phase 2, Phase 3	Carboplatin;Metformin Hydrochloride;Paclitaxel
8	A Randomized Double-Blinded Trial of Estrogen Replacement Therapy Versus Placebo in Women With Stage I or II Endometrial Adenocarcinoma	Terminated	NCT00002976	Phase 3	conjugated estrogens
9	The Effect of Neoadjuvant Depot Medroxyprogesterone Acetate on Glandular Cellularity in Women With Complex Atypical Hyperplasia or Grade 1-2 Endometrial Adenocarcinoma Awaiting Hysterectomy	Unknown status	NCT02335203	Phase 2	Depot medroxyprogesterone acetate
10	A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients With Early Stage Cancer of the Endometrium	Unknown status	NCT01686126	Phase 2	Levonorgestrel;Metformin
11	Phase II Study of Fertility-sparing Management Using High-dose Oral Progestin in Young Women With Stage I Endometrial Adenocarcinoma With Grade 2 Differentiation or Superficial Myomectomy Invasion	Unknown status	NCT03567655	Phase 2	Farlutal tab. 500mg/ Pfizer
12	A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma	Completed	NCT00478426	Phase 2	Sunitinib Malate
13	A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations	Completed	NCT02728258	Phase 2	Copanlisib
14	A Phase II Pilot Investigation Of The Relationship Of Short Term Depo-Provera (Medroxyprogesterone Acetate) Exposure To The Morphologic , Biochemical, And Molecular Changes In Primary Endometroid Adenocarcinoma of the Uterine Corpus	Completed	NCT00064025	Phase 2	Medroxyprogesterone
15	A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium	Completed	NCT01210222	Phase 2
16	Efficacy of the Oncoxin-Viusid® Oral Solution in Reducing the Adverse Reactions of Chemotherapy and Radiotherapy in Patients Diagnosed With Cervical Cancer and Endometrial Adenocarcinoma.	Completed	NCT03540407	Phase 2
17	Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma	Completed	NCT01968317	Phase 2	Megestrol acetate and metformin;Megestrol acetate
18	Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma	Completed	NCT02549209	Phase 2	Pembrolizumab;Paclitaxel;Carboplatin
19	Phase II Trial of Paclitaxel and Carboplatin With Amifostine in Advanced Recurrent or Refractory Endometrial Adenocarcinoma	Completed	NCT00003127	Phase 2	amifostine trihydrate;carboplatin;paclitaxel
20	A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT00820898	Phase 2	Gemcitabine Hydrochloride
21	A Phase II Study of CCI-779 in Patients With Metastatic and/or Locally Advanced Recurrent Endometrial Cancer	Completed	NCT00072176	Phase 2	temsirolimus
22	A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer	Completed	NCT01005329	Phase 2	Carboplatin;Cisplatin;Paclitaxel
23	A Phase II Evaluation of Trastuzumab (MoAb HER2) in Patients With Advanced, Recurrent or Persistent Endometrial Carcinoma With or Without Prior Chemotherapy	Completed	NCT00006089	Phase 2
24	A Phase II Evaluation of Brivanib (BMS582664), an Oral, Multitargeted Growth Factor Tyrosine Kinase Inhibitor in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT00888173	Phase 2	Brivanib Alaninate
25	A Phase II Evaluation of Thalidomide (NSC #66847, IND 48832) in the Treatment of Recurrent of Persistent Endometrial Carcinoma	Completed	NCT00025467	Phase 2	thalidomide
26	A Phase II Evaluation of AZD6244 (NSC #748727) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01011933	Phase 2	Selumetinib
27	A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01132820	Phase 2	Cediranib Maleate
28	A Phase II Evaluation of Ixabepilone (BMS-247550) [NCI-Supplied Agent, NSC #710428]) in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT00095979	Phase 2	ixabepilone
29	A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01642082	Phase 2
30	A Phase II Evaluation of BIBF 1120 in the Treatment of Recurrent or Persistent Endometrial Carcinoma	Completed	NCT01225887	Phase 2	Nintedanib
31	A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer	Completed	NCT01307631	Phase 2	Akt Inhibitor MK2206
32	A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women	Completed	NCT01877564	Phase 2	Metformin
33	A Phase II, Randomized Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (LEE011) in Patients With Advanced or Recurrent Endometrial Carcinoma	Recruiting	NCT03008408	Phase 2	Everolimus;Letrozole;Ribociclib
34	Phase II Study of the Levonorgestrel Intrauterine Device Alone or in Combination With the mTORC1 Inhibitor, Everolimus, for the Treatment of Complex Atypical Hyperplasia and Stage Ia Grade 1 Endometrial Cancer	Recruiting	NCT02397083	Phase 2	Everolimus
35	A Phase II Clinical Trial Evaluating the Combination of Onapristone With Anastrozole for Women With Refractory Hormone Receptor Positive Endometrial Cancer	Recruiting	NCT04719273	Phase 2	Extended-release Onapristone;Anastrozole
36	A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma	Recruiting	NCT05112601	Phase 2
37	A Phase 1b/2 Basket Study of ACR-368 as Monotherapy and in Combination With Gemcitabine in Adult Subjects With Platinum-Resistant Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma Based on Acrivon OncoSignature® Status	Recruiting	NCT05548296	Phase 1, Phase 2	ACR-368;Gemcitabine
38	A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies	Recruiting	NCT03221400	Phase 1, Phase 2	PEN-866 Sodium;fluorouracil;Folinic acid;Niraparib
39	Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects Who Have Advanced, Recurrent or Refractory FRα Overexpressing Tumors	Recruiting	NCT05001282	Phase 1, Phase 2	ELU001
40	Phase II Study of Fulvestrant in Combination With Abemaciclib in Hormone Receptor Positive Adenocarcinoma of Endometrium	Recruiting	NCT03643510	Phase 2	Fulvestrant;Abemaciclib
41	Pilot Study of Daily Exemestane in Women With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer	Active, not recruiting	NCT03300557	Phase 2	Exemestane
42	A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus	Active, not recruiting	NCT00492778	Phase 2	Cisplatin
43	A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma	Active, not recruiting	NCT03348631	Phase 2	Tazemetostat
44	A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer	Active, not recruiting	NCT02684227	Phase 2	Carboplatin;Enzalutamide;Paclitaxel
45	A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma	Active, not recruiting	NCT02730923	Phase 1, Phase 2	AZD2014;Anastrozole
46	A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056)	Active, not recruiting	NCT04106414	Phase 2	Nivolumab;BMS- 986205
47	A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC #704865), Paclitaxel/Carboplatin/Temsirolimus (NSC #683864) and Ixabepilone (NSC #710428)/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer	Active, not recruiting	NCT00977574	Phase 2	Carboplatin;Ixabepilone;Paclitaxel;Temsirolimus
48	A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Active, not recruiting	NCT02208375	Phase 1, Phase 2	Capivasertib;Olaparib;Vistusertib
49	A Phase IB and Randomized Phase II Trial of Megestrol Acetate With or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer	Not yet recruiting	NCT05538897	Phase 1, Phase 2	Ipatasertib;Megestrol Acetate
50	A Phase II Trial of Trisenox in Women With Recurrent or Metastatic Endometrial Adenocarcinoma	Terminated	NCT01184053	Phase 2	Arsenic trioxide

Search NIH Clinical Center for Endometrial Adenocarcinoma

Sources

Genetic Tests for Endometrial Adenocarcinoma

Sources

Anatomical Context for Endometrial Adenocarcinoma

Organs/tissues related to Endometrial Adenocarcinoma:

MalaCards : Uterus, Lymph Node, Ovary, Breast, Endothelial, Cervix, Adipocyte

Sources

Publications for Endometrial Adenocarcinoma

Articles related to Endometrial Adenocarcinoma:

(show top 50) (show all 3766)

#	Title	Authors	PMID	Year
1	Prospective enterprise-level molecular genotyping of a cohort of cancer patients. ⁵	MacConaill LE...Lindeman NI	25157968	2014
2	The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. ⁵	Byron SA...Pollock PM	23908597	2013
3	FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. ⁵	Guagnano V...Graus-Porta D	23002168	2012
4	Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. ⁵	Leslie KK...Rose PG	22885469	2012
5	Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. ⁵	Gozgit JM...Rivera VM	22238366	2012
6	High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. ⁵	Cheung LW...Mills GB	21984976	2011
7	AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. ⁵	Cohen Y...Rechavi G	19853286	2010
8	Drug-sensitive FGFR2 mutations in endometrial carcinoma. ⁵	Dutt A...Greulich H	18552176	2008
9	Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. ⁴⁶	Wu W...Liang X	19077565	2009
10	Iris metastasis from endometrial carcinoma: A challenging diagnosis and individualized eye-sparing treatment. ⁶²	Agostara AG...Carlo Stella G	36388758	2022
11	A Constellation of Rare Gynecological Malignancies and Familial Adenomatous Polyposis Gastrointestinal Adenocarcinoma: A Case Report. ⁶²	Gill SJ...Neveu J	36302191	2022
12	Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol. ⁶²	Zhao X...Liu Z	36333773	2022
13	Metastatic Endometrioid Carcinoma Mimicking a Subungual Melanoma. ⁶²	Glavy JC...Flint JH	36361369	2022
14	VALIDATION OF A PANEL OF BIOMARKERS ASSOCIATED WITH AGGRESSIVE PHENOTYPE OF ENDOMETRIOID CARCINOMA OF ENDOMETRIUM. ⁶²	Buchynska LG...Glushchenko NM	36325701	2022
15	OPEC study: An international multicenter study of ovarian preservation in endometrial cancers. ⁶²	Akgor U...Gultekin M	35323994	2022
16	Significance of differential expression of OLFM4 in the development of endometrial adenocarcinoma. ⁶²	Huang D...Li H	36451436	2022
17	Platelet-derived exosomes induce cell proliferation and wound healing in human endometrial cells. ⁶²	Miller CM...Khan Z	36193669	2022
18	Mesonephric-Like Adenocarcinomas a Rare Tumor: The Importance of Diagnosis. ⁶²	Restaino S...Vizzielli G	36361332	2022
19	Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study. ⁶²	Kurnit KC...Soliman PT	36243601	2022
20	[Aneurysm of the inferior vena cava : A case report]. ⁶²	Marsafi O...Wakrim S	35718552	2022
21	Diagnostic utility of ThinPrep Imaging System® for detecting atypical glandular cells in cervical smear samples. ⁶²	Akca Y...Erkilic S	36308412	2022
22	Metastatic ovarian disease following surgical management of grade 1 endometrial endometrioid adenocarcinoma confined to the endometrium; a case report and review of the literature. ⁶²	Hill S...Pather S	35967832	2022
23	Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium. ⁶²	Barber EL...Matei D	36388466	2022
24	An MSH6 germline pathogenic variant p.Gly162Ter associated with Lynch syndrome. ⁶²	Vostrukhina OA...Verbenko VN	36289196	2022
25	Loss of HOXA10 causes endometrial hyperplasia progressing to endometrial cancer. ⁶²	Mishra A...Modi D	35917434	2022
26	[Familial endometrial adenocarcinoma: MSH6 variant of unknown significance in the presence of phenocopy, what should be done?] ⁶²	Perez-Rodriguez A...Sagasta A	36075656	2022
27	Endometrial Cells Acutely Exposed to Phthalates In Vitro Do Not Phenocopy Endometriosis. ⁶²	Gonzalez-Martin R...Dominguez F	36232341	2022
28	[Retroperitoneal lymphadenopathy trans-vertebral image-guided biopsy: a case report] ⁶²	Rendon FO...Borensztein MA	36149066	2022
29	BAT26 Only Microsatellite Instability with High Tumor Mutation Burden-A Rare Entity Associated with PTEN Protein Loss and High PD-L1 Expression. ⁶²	Kang SY...Kim KM	36142641	2022
30	12-O-Tetradecanoylphorbol 13-acetate promotes proliferation and epithelial-mesenchymal transition in HHUA cells cultured on collagen type I gel: A feasible model to find new therapies for endometrial diseases. ⁶²	Hanaki Y...Sato M	35973688	2022
31	The complex relationship between infertility and female genital tract cancer: A review. ⁶²	Alessandra F...Giovanni S	34338095	2022
32	An unusual malignant main bile duct stricture: a biliary metastasis of endometrial adenocarcinoma. ⁶²	Mayer P...Habersetzer F	35926532	2022
33	[Corrigendum] BMI‑1 promotes invasion and metastasis in endometrial adenocarcinoma and is a poor prognostic factor. ⁶²	Yu J...Li L	35730621	2022
34	The impact of uterine adenomyosis on the histopathological risk factors and survival in patients with endometrial adenocarcinoma. ⁶²	Yetimalar MH...Yigit S	35260040	2022
35	The role of potassium channels in the proliferation and migration of endometrial adenocarcinoma HEC1-A cells. ⁶²	Erdem Kis E...Un I	35553332	2022
36	Endometrial hyperplasia as a risk factor of endometrial cancer. ⁶²	Nees LK...Wallwiener M	35001185	2022
37	Metastatic Cholangiocarcinoma to the Uterus Morphologically Imitating Primary Intestinal-type Endometrioid Adenocarcinoma. ⁶²	Kostelecky N...Krigman H	36044318	2022
38	Intestinal type adenocarcinoma of the endometrium with signet ring cells, a rare aggressive variant. ⁶²	Seay K...Goldberg GL	35898198	2022
39	Indications for Adjuvant Radiation Therapy in Patients With pN0(i +) Adenocarcinoma of the Endometrium. ⁶²	Musunuru HB...Beriwal S	35248784	2022
40	DSCAM-AS1 Long Non-Coding RNA Exerts Oncogenic Functions in Endometrial Adenocarcinoma via Activation of a Tumor-Promoting Transcriptome Profile. ⁶²	Treeck O...Ortmann O	35885035	2022
41	Ichthyosis uteri associated with squamous cell carcinoma of the endometrium - a case report. ⁶²	Puljiz M...Veliki Dalic I	35848086	2022
42	Safety of ovarian preservation for premenopausal patients with FIGO stage I grade 2 and 3 endometrioid endometrial adenocarcinoma. ⁶²	Nasioudis D...Latif NA	35882426	2022
43	An Evaluation of the Immunohistochemical Expression of Mismatch Repair Proteins (MSH2, MSH6, MLH1, and PMS2) in Prostate Adenocarcinoma. ⁶²	Javeed S...Chughtai AS	36051725	2022
44	Synchronous benign Brenner's tumor of the ovary with leiomyoma and endometrial adenocarcinoma in a postmenopausal female. ⁶²	Okoye JO	36149192	2022
45	First pointwise encoding time reduction with radial acquisition (PETRA) implementation for catheter detection in interstitial high-dose-rate (HDR) brachytherapy. ⁶²	Kaza E...Buzurovic I	35337748	2022
46	Ruptured granulosa cell tumor of the ovary presenting with catastrophic intra-abdominal hemorrhage: A case report. ⁶²	Smith AD...Muscarella P	35724501	2022
47	The impact of tumor size and histology on local control when utilizing high-dose-rate interstitial brachytherapy for gynecologic malignancies. ⁶²	Schiff JP...Grigsby PW	35370010	2022
48	Development and Validation of an MRI-based Radiomics Nomogram for Assessing Deep Myometrial Invasion in Early Stage Endometrial Adenocarcinoma. ⁶²	Wang Y...Wu K	35778306	2022
49	YTHDF2 is a novel diagnostic marker of endometrial adenocarcinoma and endometrial atypical hyperplasia/ intraepithelial neoplasia. ⁶²	Bian PP...Xiong ZT	35512522	2022
50	Histopathological and genetic features of mismatch repair-deficient high-grade prostate cancer. ⁶²	Wyvekens N...Acosta AM	35395112	2022

Sources

Genes for Endometrial Adenocarcinoma

Genes related to Endometrial Adenocarcinoma (0 elite genes):

(show all 35)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MALAT1	Metastasis Associated Lung Adenocarcinoma Transcript 1	RNA Gene	150	Experimental evidence: Regulation ³⁷	25085246
2	MIR204	MicroRNA 204	RNA Gene	53.5	Unspecified ⁴⁶ DISEASES inferred ¹⁴	19077565
3	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	30.86	Likely pathogenic ⁵ DISEASES inferred ¹⁴	25157968 19853286
4	EGFR	Epidermal Growth Factor Receptor	Protein Coding	30.45	Likely pathogenic ⁵ DISEASES inferred ¹⁴	22885469
5	FGFR2	Fibroblast Growth Factor Receptor 2	Protein Coding	29.7	Likely pathogenic ⁵ DISEASES inferred ¹⁴	18552176 22238366 23002168 (more) 23908597
6	PIK3R2	Phosphoinositide-3-Kinase Regulatory Subunit 2	Protein Coding	28.3	Likely pathogenic ⁵ DISEASES inferred ¹⁴	21984976
7	THEMIS2	Thymocyte Selection Associated Family Member 2	Protein Coding	20.76	DISEASES inferred ¹⁴ GeneCards inferred via : Publications Expressions (show sections)
8	RHOXF1	Rhox Homeobox Family Member 1	Protein Coding	10.83	DISEASES inferred ¹⁴ GeneCards inferred via : Expressions (show sections)
9	MIR193A	MicroRNA 193a	RNA Gene	9.07	DISEASES inferred ¹⁴ ¹⁴
10	MIR200A	MicroRNA 200a	RNA Gene	8.06	DISEASES inferred ¹⁴ ¹⁴
11	BET1L	Bet1 Golgi Vesicular Membrane Trafficking Protein Like	Protein Coding	7.97	GeneCards inferred via : Summaries (show sections)
12	MIR202	MicroRNA 202	RNA Gene	7.85	DISEASES inferred ¹⁴ ¹⁴
13	MIR200B	MicroRNA 200b	RNA Gene	7.72	DISEASES inferred ¹⁴ ¹⁴
14	PGR	Progesterone Receptor	Protein Coding	7.29	DISEASES inferred ¹⁴
15	ESR1	Estrogen Receptor 1	Protein Coding	7.19	DISEASES inferred ¹⁴
16	MIR152	MicroRNA 152	RNA Gene	7.09	DISEASES inferred ¹⁴ ¹⁴
17	NDC80	NDC80 Kinetochore Complex Component	Protein Coding	6.9	DISEASES inferred ¹⁴
18	TP53	Tumor Protein P53	Protein Coding	6.75	DISEASES inferred ¹⁴
19	PTEN	Phosphatase And Tensin Homolog	Protein Coding	6.75	DISEASES inferred ¹⁴
20	MIR148B	MicroRNA 148b	RNA Gene	6.48	DISEASES inferred ¹⁴ ¹⁴
21	MIR199A1	MicroRNA 199a-1	RNA Gene	6.46	DISEASES inferred ¹⁴ ¹⁴
22	MIR34A	MicroRNA 34a	RNA Gene	6.42	DISEASES inferred ¹⁴ ¹⁴
23	MLH1	MutL Homolog 1	Protein Coding	6.35	DISEASES inferred ¹⁴
24	MSH6	MutS Homolog 6	Protein Coding	6.32	DISEASES inferred ¹⁴
25	PMS2	PMS1 Homolog 2, Mismatch Repair System Component	Protein Coding	6.3	DISEASES inferred ¹⁴
26	SERPINA3	Serpin Family A Member 3	Protein Coding	6.28	DISEASES inferred ¹⁴ ¹⁴
27	MIR34C	MicroRNA 34c	RNA Gene	6.23	DISEASES inferred ¹⁴ ¹⁴
28	POLE	DNA Polymerase Epsilon, Catalytic Subunit	Protein Coding	6.21	DISEASES inferred ¹⁴
29	MSH2	MutS Homolog 2	Protein Coding	6.2	DISEASES inferred ¹⁴
30	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	6.13	DISEASES inferred ¹⁴ ¹⁴
31	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	6.12	DISEASES inferred ¹⁴
32	PAX8	Paired Box 8	Protein Coding	6.11	DISEASES inferred ¹⁴
33	KRT7	Keratin 7	Protein Coding	6.09	DISEASES inferred ¹⁴
34	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	6.01	DISEASES inferred ¹⁴
35	EPM2A	EPM2A Glucan Phosphatase, Laforin	Protein Coding	6.01	DISEASES inferred ¹⁴

Sources

Variations for Endometrial Adenocarcinoma

ClinVar genetic disease variations for Endometrial Adenocarcinoma:

⁵ (show all 18)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	EGFR	NM_005228.5(EGFR):c.2068G>A (p.Glu690Lys)	SNV	Likely Pathogenic	376152	rs1057519794	GRCh37: 7:55241620-55241620 GRCh38: 7:55173927-55173927
2	PIK3R2	NM_005027.4(PIK3R2):c.1681A>G (p.Asn561Asp)	SNV	Likely Pathogenic	376165	rs1057519801	GRCh37: 19:18278061-18278061 GRCh38: 19:18167251-18167251
3	AKT1	NM_001382430.1(AKT1):c.49G>A (p.Glu17Lys)	SNV	Likely Pathogenic	13983	rs121434592	GRCh37: 14:105246551-105246551 GRCh38: 14:104780214-104780214
4	FGFR2	NM_000141.5(FGFR2):c.1975A>G (p.Lys659Glu)	SNV	Likely Pathogenic	376153	rs1057519795	GRCh37: 10:123247516-123247516 GRCh38: 10:121488002-121488002
5	FGFR2	NM_000141.5(FGFR2):c.1605G>A (p.Met535Ile)	SNV	Likely Pathogenic	376164	rs1057519800	GRCh37: 10:123258076-123258076 GRCh38: 10:121498562-121498562
6	FGFR2	NM_000141.5(FGFR2):c.1690G>A (p.Val564Ile)	SNV	Likely Pathogenic	376155	rs1057519797	GRCh37: 10:123256219-123256219 GRCh38: 10:121496705-121496705
7	FGFR2	NM_000141.5(FGFR2):c.1605G>T (p.Met535Ile)	SNV	Likely Pathogenic	376162	rs1057519800	GRCh37: 10:123258076-123258076 GRCh38: 10:121498562-121498562
8	FGFR2	NM_000141.5(FGFR2):c.1611G>T (p.Met537Ile)	SNV	Likely Pathogenic	376159	rs1057519799	GRCh37: 10:123258070-123258070 GRCh38: 10:121498556-121498556
9	FGFR2	NM_000141.5(FGFR2):c.1849T>A (p.Leu617Met)	SNV	Likely Pathogenic	376154	rs1057519796	GRCh37: 10:123256060-123256060 GRCh38: 10:121496546-121496546
10	FGFR2	NM_000141.5(FGFR2):c.755C>G (p.Ser252Trp)	SNV	Likely Pathogenic	13272	rs79184941	GRCh37: 10:123279677-123279677 GRCh38: 10:121520163-121520163
11	FGFR2	NM_000141.5(FGFR2):c.1645A>C (p.Asn549His)	SNV	Likely Pathogenic	374821	rs1057519045	GRCh37: 10:123258036-123258036 GRCh38: 10:121498522-121498522
12	FGFR2	NM_000141.5(FGFR2):c.1647T>A (p.Asn549Lys)	SNV	Likely Pathogenic	376157	rs121913476	GRCh37: 10:123258034-123258034 GRCh38: 10:121498520-121498520
13	FGFR2	NM_000141.5(FGFR2):c.1647T>G (p.Asn549Lys)	SNV	Likely Pathogenic	376156	rs121913476	GRCh37: 10:123258034-123258034 GRCh38: 10:121498520-121498520
14	FGFR2	NM_000141.5(FGFR2):c.1605G>C (p.Met535Ile)	SNV	Likely Pathogenic	376163	rs1057519800	GRCh37: 10:123258076-123258076 GRCh38: 10:121498562-121498562
15	FGFR2	NM_000141.5(FGFR2):c.1611G>C (p.Met537Ile)	SNV	Likely Pathogenic	376160	rs1057519799	GRCh37: 10:123258070-123258070 GRCh38: 10:121498556-121498556
16	FGFR2	NM_000141.5(FGFR2):c.1694A>G (p.Glu565Gly)	SNV	Likely Pathogenic	374823	rs121918506	GRCh37: 10:123256215-123256215 GRCh38: 10:121496701-121496701
17	FGFR2	NM_000141.5(FGFR2):c.1611G>A (p.Met537Ile)	SNV	Likely Pathogenic	376161	rs1057519799	GRCh37: 10:123258070-123258070 GRCh38: 10:121498556-121498556
18	FGFR2	NM_000141.5(FGFR2):c.1639A>G (p.Ile547Val)	SNV	Likely Pathogenic	376158	rs1057519798	GRCh37: 10:123258042-123258042 GRCh38: 10:121498528-121498528

Cosmic variations for Endometrial Adenocarcinoma:

⁸ (show top 50) (show all 13016)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM147988734	TSC1	endometrium,NS,carcinoma,adenocarcinoma	c.2695C>G	p.Q899E	9:132897538-132897538	15
2	COSM151335840	TSC1	endometrium,NS,carcinoma,adenocarcinoma	c.2698C>G	p.Q900E	9:132897538-132897538	15
3	COSM111045067	TSC1	endometrium,NS,carcinoma,adenocarcinoma	c.2698C>G	p.Q900E	9:132897538-132897538	15
4	COSM148040940	TSC1	endometrium,NS,carcinoma,adenocarcinoma	c.2680C>G	p.Q894E	9:132897538-132897538	15
5	COSM151876398	TSC1	endometrium,NS,carcinoma,adenocarcinoma	c.2698C>G	p.Q900E	9:132897538-132897538	15
6	COSM150680210	TSC1	endometrium,NS,carcinoma,adenocarcinoma	c.2683C>G	p.Q895E	9:132897538-132897538	15
7	COSM150540031	TSC1	endometrium,NS,carcinoma,adenocarcinoma	c.2545C>G	p.Q849E	9:132897538-132897538	15
8	COSM149044571	TSC1	endometrium,NS,carcinoma,adenocarcinoma	c.2695C>G	p.Q899E	9:132897538-132897538	15
9	COSM85725394	TSC1	endometrium,NS,carcinoma,adenocarcinoma	c.2698C>G	p.Q900E	9:132897538-132897538	15
10	COSM133092250	TSC1	endometrium,NS,carcinoma,adenocarcinoma	c.2545C>G	p.Q849E	9:132897538-132897538	15
11	COSM93207461	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.761T>G	p.I254S	17:7674202-7674202	15
12	COSM144099306	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.-89T>G	p.?	17:7675223-7675223	15
13	COSM112253807	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.733G>A	p.G245S	17:7674230-7674230	15
14	COSM87925973	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.761T>G	p.I254S	17:7674202-7674202	15
15	COSM143157028	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.340C>T	p.R114C	17:7673803-7673803	15
16	COSM143162603	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.217A>G	p.I73V	17:7674269-7674269	15
17	COSM142560558	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.727C>T	p.R243W	17:7673776-7673776	15
18	COSM121901025	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.365T>G	p.I122S	17:7674202-7674202	15
19	COSM111759017	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.722C>G	p.S241C	17:7674241-7674241	15
20	COSM122734486	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.520C>T	p.R174*	17:7673704-7673704	15
21	COSM144100203	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.26A>G	p.H9R	17:7675109-7675109	15
22	COSM121876472	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.448C>T	p.R150W	17:7673776-7673776	15
23	COSM121881481	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.445G>A	p.D149N	17:7673779-7673779	15
24	COSM144651436	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.625C>T	p.R209W	17:7674221-7674221	15
25	COSM143946029	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.*43C>T	p.?	17:7670685-7670685	15
26	COSM87917930	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.503A>G	p.H168R	17:7675109-7675109	15
27	COSM144087273	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.265C>T	p.R89W	17:7674221-7674221	15
28	COSM144653327	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.*131C>T	p.?	17:7670685-7670685	15
29	COSM144675014	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.644T>G	p.I215S	17:7674202-7674202	15
30	COSM142566974	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.577A>G	p.I193V	17:7674269-7674269	15
31	COSM93185597	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.637C>T	p.R213*	17:7674894-7674894	15
32	COSM145018055	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.799C>T	p.R267*	17:7673704-7673704	15
33	COSM112253979	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.916C>T	p.R306*	17:7673704-7673704	15
34	COSM122275678	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.445G>A	p.D149N	17:7673779-7673779	15
35	COSM143157019	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.265C>T	p.R89W	17:7674221-7674221	15
36	COSM144659060	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.577A>G	p.I193V	17:7674269-7674269	15
37	COSM142562047	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.520C>T	p.R174*	17:7674894-7674894	15
38	COSM143158609	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.*131C>T	p.?	17:7670685-7670685	15
39	COSM122750344	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.107A>G	p.H36R	17:7675109-7675109	15
40	COSM144088597	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.547C>T	p.R183*	17:7670685-7670685	15
41	COSM142837646	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.916C>T	p.R306*	17:7673704-7673704	15
42	COSM143958875	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.26A>G	p.H9R	17:7675109-7675109	15
43	COSM144090100	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.364G>A	p.D122N	17:7673779-7673779	15
44	COSM143949774	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.217A>G	p.I73V	17:7674269-7674269	15
45	COSM93184097	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.916C>T	p.R306*	17:7673704-7673704	15
46	COSM111763404	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.841G>A	p.D281N	17:7673779-7673779	15
47	COSM111765865	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.694A>G	p.I232V	17:7674269-7674269	15
48	COSM105620760	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.782+477C>T	p.?	17:7673704-7673704	15
49	COSM121893481	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.-8T>G	p.?	17:7675223-7675223	15
50	COSM143156960	TP53	endometrium,NS,carcinoma,adenocarcinoma	c.256G>A	p.G86S	17:7674230-7674230	15

Sources

Expression for Endometrial Adenocarcinoma

Search GEO for disease gene expression data for Endometrial Adenocarcinoma.

Sources

Pathways for Endometrial Adenocarcinoma

Pathways related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)

#	Super pathways	Score	Top Affiliating Genes
1	Signal Transduction ⁶⁶	13.75	TP53 PTEN PIK3R2 PGR NDC80 FGFR2
2	Phospholipase-C Pathway ⁶⁴ Show member pathways PTEN Pathway ⁶⁴	13.02	TP53 PTEN PIK3R2 FGFR2 EGFR AKT1
3	PIP3 activates AKT signaling ⁶⁶ Show member pathways Intracellular signaling by second messengers ⁶⁶ PTEN Regulation ⁶⁶ Regulation of PTEN gene transcription ⁶⁶ Regulation of PTEN localization ⁶⁶	12.92	AKT1 EGFR ESR1 FGFR2 PIK3R2 PTEN
4	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.89	TP53 PTEN PIK3R2 FGFR2 EGFR AKT1
5	NFAT and Cardiac Hypertrophy ⁶⁴ Show member pathways IGF1R Signaling ⁶⁴ Signaling Involved in Cardiac Hypertrophy ⁶⁴	12.83	PTEN PIK3R2 FGFR2 EGFR AKT1
6	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.73	PIK3R2 PGR FGFR2 ESR1 EGFR AKT1
7	Malignant pleural mesothelioma ⁷⁴	12.64	TP53 PTEN FGFR2 EGFR AKT1
8	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.61	TP53 PIK3R2 FGFR2 EGFR AKT1
9	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.53	TP53 PTEN PIK3R2 FGFR2 EGFR AKT1
10	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.46	AKT1 EGFR PIK3R2 TP53
11	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ⁶⁶ Show member pathways Constitutive Signaling by Aberrant PI3K in Cancer ⁶⁶ Negative regulation of the PI3K/AKT network ⁶⁶ PI3K/AKT Signaling in Cancer ⁶⁶	12.45	PTEN PIK3R2 FGFR2 ESR1 EGFR AKT1
12	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.38	PIK3R2 ESR1 EGFR AKT1
13	MAPK signaling pathway ⁷⁴	12.37	TP53 FGFR2 EGFR AKT1
14	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.34	TP53 PTEN PIK3R2 ESR1 AKT1
15	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.31	TP53 PIK3R2 FGFR2 EGFR AKT1
16	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.28	PIK3R2 ESR1 EGFR AKT1
17	Focal adhesion ⁷⁴	12.24	AKT1 EGFR PIK3R2 PTEN
18	Development IGF-1 receptor signaling ²² Show member pathways Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.21	TP53 PTEN PIK3R2 AKT1
19	Ras signaling ⁷⁴	12.19	PIK3R2 FGFR2 EGFR AKT1
20	VEGF Signaling Pathway ⁶⁰ ⁶⁷ Show member pathways Nanoparticle-mediated activation of receptor signaling ⁷⁴ TGF-beta Signaling ⁶⁷	12.15	PTEN FGFR2 EGFR AKT1
21	Colorectal Cancer Metastasis ⁶⁴	12.13	AKT1 EGFR PIK3R2 TP53
22	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	11.98	AKT1 EGFR FGFR2 PIK3R2 PTEN TP53
23	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	11.94	AKT1 EGFR PIK3R2 TP53
24	Integrated breast cancer pathway ⁷⁴	11.91	TP53 PTEN PIK3R2 ESR1 EGFR AKT1
25	DNA damage response (only ATM dependent) ⁷⁴	11.89	TP53 PTEN PIK3R2
26	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²²	11.87	PTEN PIK3R2 EGFR AKT1
27	TGF-beta Signaling Pathways ⁶⁵	11.86	PIK3R2 ESR1 AKT1
28	PI3K / Akt Signaling ³	11.84	PTEN PIK3R2 AKT1
29	TP53 Regulates Metabolic Genes ⁶⁶	11.81	TP53 PTEN AKT1
30	Clear cell renal cell carcinoma pathways ⁷⁴	11.8	AKT1 EGFR PTEN
31	mTOR Signaling ⁶⁵	11.78	TP53 PTEN PIK3R2 FGFR2 EGFR AKT1
32	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.76	TP53 PIK3R2 AKT1
33	Small cell lung cancer ⁷⁴	11.74	TP53 PTEN PIK3R2 AKT1
34	Burn wound healing ⁷⁴	11.73	TP53 FGFR2 AKT1
35	16p11.2 proximal deletion syndrome ⁷⁴	11.71	TP53 PTEN ESR1
36	AP-1 transcription factor network ⁶¹	11.68	TP53 PTEN ESR1
37	Regulation of Telomerase ⁶¹	11.67	ESR1 EGFR AKT1
38	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	11.66	TP53 PTEN PIK3R2 PGR FGFR2 ESR1
39	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.62	TP53 PTEN AKT1
40	Copper homeostasis ⁷⁴ Show member pathways Copper metabolism ⁷⁴ Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1) ⁶⁶	11.58	TP53 PTEN AKT1
41	Bladder cancer ⁷⁴	11.38	TP53 PIK3R2 EGFR
42	Ovarian tumor domain proteases ⁶⁶	11.36	TP53 PTEN ESR1
43	miRNA targets in ECM and membrane receptors ⁷⁴	11.34	MIR200B MIR200A MIR148B
44	Integrated cancer pathway ⁷⁴	11.33	TP53 PTEN AKT1
45	Transcription_Transcription factor Tubby signaling pathways ²²	11.3	TP53 PIK3R2 EGFR
46	Head and neck squamous cell carcinoma ⁷⁴	11.3	TP53 PTEN PIK3R2 FGFR2 EGFR AKT1
47	Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) ⁷⁴	11.25	PGR ESR1 EGFR
48	PI3K-AKT-mTOR signaling pathway and therapeutic opportunities ⁷⁴	11.2	PTEN PIK3R2 AKT1
49	Mammary gland development pathway - Embryonic development (Stage 1 of 4) ⁷⁴	10.84	MIR200B MIR200A AKT1
50	Mammary gland development pathway - Puberty (Stage 2 of 4) ⁷⁴	10.81	PGR ESR1

Sources

GO Terms for Endometrial Adenocarcinoma

Cellular components related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	RISC complex	GO:0016442	9.4	MIR204 MIR202 MIR200B MIR200A MIR152 MIR148B

Biological processes related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of gene expression	GO:0010629	10.03	TP53 PGR MIR200B ESR1 AKT1
2	phosphatidylinositol 3-kinase signaling	GO:0014065	9.85	AKT1 PIK3R2 PTEN
3	prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis	GO:0060527	9.71	FGFR2 ESR1
4	negative regulation of miRNA maturation	GO:1903799	9.65	TP53 ESR1
5	positive regulation of RNA polymerase II transcription preinitiation complex assembly	GO:0045899	9.62	TP53 ESR1
6	positive regulation of miRNA maturation	GO:1903800	9.46	TP53 EGFR
7	response to UV-A	GO:0070141	9.46	EGFR AKT1
8	cellular response to decreased oxygen levels	GO:0036294	9.43	PTEN AKT1
9	prostate epithelial cord elongation	GO:0060523	9.26	FGFR2 ESR1
10	negative regulation of blood vessel endothelial cell migration	GO:0043537	8.92	MIR204 MIR200B MIR193A MIR152

Molecular functions related to Endometrial Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	enzyme binding	GO:0019899	10.03	TP53 PTEN PGR ESR1 EGFR AKT1
2	nitric-oxide synthase regulator activity	GO:0030235	9.63	ESR1 EGFR AKT1
3	mRNA 3'-UTR binding	GO:0003730	9.5	TP53 MIR204 MIR200B MIR193A MIR152 MIR148B
4	mRNA base-pairing translational repressor activity	GO:1903231	9.1	MIR204 MIR200B MIR200A MIR193A MIR152 MIR148B